Innovative Bispecific Nanobody Targeting ALB and IL6R for Rheumatoid Arthritis Therapy

VHH-P763 is a humanized bispecific nanobody designed to target both albumin (ALB) and interleukin 6 receptor (IL6R), two critical molecules implicated in inflammation and immune regulation. Currently in the Biological Testing stage of development, VHH-P763 harnesses the unique properties of single-domain antibodies to achieve highly specific binding to its targets. By engaging both ALB and IL6R, the molecule holds potential as an advanced treatment option for rheumatoid arthritis, addressing key pathogenic pathways involved in the disease. The construct is produced in E. coli cells, enabling scalable and efficient manufacturing.

Licensing Opportunity

VHH-P763 is available for out-licensing and collaborative development. We welcome inquiries from partners interested in advancing innovative biologics for the treatment of autoimmune and inflammatory diseases.

Development Phase

Modality

VHH-P763 is a bispecific nanobody, combining variable domains that specifically recognize IL6R and ALB, linked via a flexible 9GS peptide sequence. Engineered as a single-domain antibody construct, it leverages the small molecular size, high stability, and superior tissue penetration characteristic of nanobodies. These properties facilitate deep joint access and robust bioavailability—critical advantages for the treatment of rheumatoid arthritis, where traditional large antibody molecules may face limitations. The E. coli expression system supports high-yield production and streamlines downstream processing, offering both scientific and commercial benefits.

Target

ALB and IL6R are the dual targets of VHH-P763. ALB, the most abundant plasma protein, is essential for maintaining oncotic pressure and serves as a carrier for various endogenous and exogenous substances, expressed predominantly in the liver and circulating in plasma. ALB can influence pharmacokinetics and tissue distribution of therapies. IL6R, a key receptor involved in immune signaling and inflammatory response, is expressed on immune cells and certain epithelial cells; it mediates the activity of interleukin-6, a cytokine with central roles in the pathogenesis of autoimmune diseases. Both ALB and IL6R are integral to disease processes in rheumatoid arthritis. Targeting ALB extends the serum half-life, while modulating IL6R can suppress pathogenic inflammation, establishing a dual-pronged therapeutic strategy with high strategic value for difficult-to-treat autoimmune diseases.

Mechanism of Action

VHH-P763 simultaneously binds to ALB and IL6R. By engaging ALB, the nanobody harnesses endogenous albumin recycling pathways, potentially extending its circulatory half-life and improving tissue distribution. The anti-IL6R component blocks IL6R-mediated signal transduction, interfering with the pro-inflammatory IL-6 pathway central to rheumatoid arthritis pathogenesis. As a signal transduction modulator, VHH-P763 is designed to suppress immune-mediated inflammation. The modularity of the nanobody platform allows for future derivatives, including antibody-drug conjugates (ADC) and multi-specific formats, broadening therapeutic applications in immune and inflammatory disorders.

Rheumatoid Arthritis

Rheumatoid arthritis is a chronic, systemic autoimmune disease characterized by persistent joint inflammation, synovial proliferation, and eventual destruction of cartilage and bone. It affects millions globally, disproportionately impacting women and leading to significant disability and decreased quality of life. Current therapeutic strategies include nonsteroidal anti-inflammatory drugs, corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biologics targeting inflammatory cytokines or immune cells. However, not all patients respond adequately, adverse effects remain a concern, and durable remission is often elusive. There remains a need for innovative therapies that offer improved efficacy, safety, and convenience. By targeting both ALB and IL6R, VHH-P763 introduces a dual-mechanism strategy that may enhance therapeutic index, reduce dosing frequency, and provide superior disease control for patients refractory to existing treatments.